Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies

• Heiner Wedemeyer ,

  * E-mail: wedemeyer.heiner@mh-hannover.de

  Affiliation Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, Hannover, Germany

  ⨯
• Xavier Forns,

  Affiliation Liver Unit, Hospital Clinic, IDIBAPS and CIBEREHD, Barcelona, Spain

  ⨯
• Christophe Hézode,

  Affiliation Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, INSERM U955, Université Paris-Est, Créteil, France

  ⨯
• Samuel S. Lee,

  Affiliation Liver Unit, University of Calgary, Calgary, Canada

  ⨯
• Astrid Scalori,

  Affiliation Global Product Development Immunology, Respiratory, Roche Products Ltd, Welwyn, United Kingdom

  ⨯
• Athina Voulgari,

  Affiliation Global Product Development Clinical Science, Roche Products Ltd, Welwyn, United Kingdom

  ⨯
• Sophie Le Pogam,

  Affiliation Clinical Development-Infectious Diseases, Genentech Inc., South San Francisco, California, United States of America

  ⨯
• Isabel Nájera,

  Affiliation Roche Pharma and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland

  ⨯
• James A. Thommes

  Affiliation Product Development Immunology, Genentech Inc., South San Francisco, California, United States of America

  ⨯